Predictors of cardiovascular damage in patients with systemic lupus erythematosus: Data from LUMINA (LXVIII), a multiethnic US cohort

Rheumatology

Volumn 48, Issue 7, 2009, Pages 817-822

  Pons Estel, Guillermo J ^a   González, Luis A ^a   Zhang, Jie ^a   Burgos, Paula I ^a   Reveille, John D ^b   Vilá, Luis M ^c   Alarcón, Graciela S ^a,d,e  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e NONE   (United States)

Author keywords

Atherosclerosis; C reactive protein; Cardiovascular; Damage; Ethnicity; Lupus

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; WARFARIN;

ADULT; AFRICAN AMERICAN; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAUCASIAN; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS SURGERY; DISEASE DURATION; DRUG EFFICACY; DRUG MEGADOSE; EDUCATION; ETHNICITY; FEMALE; HEART INFARCTION; HISPANIC; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SOCIOECONOMICS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AFRICAN AMERICANS; AGE FACTORS; AGED; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; EDUCATIONAL STATUS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; RISK FACTORS; SEX FACTORS;

EID: 67650096909     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep102     Document Type: Article

References (51)

1. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-5.
2. Bernatsky S, Boivin JF, Joseph L et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54:2550-7.
3. Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham study. Am J Epidemiol 1997;145:408-15.
4. Rosner S, Ginzler EM, Diamond HS et al. A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum 1982;25:612-17.
5. Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: Prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 1992;71:291-302.
6. Esdaile JM, Abrahamowicz M, Grodzicky T et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7.
7. Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest J Jr. Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol 1999;26:2363-8.
8. Toloza SMA, Uribe AG, McGwin G Jr et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XXIII: Baseline predictors of vascular events. Arthritis Rheum 2004;50:3947-57.
9. Gladman D, Ginzler E, Goldsmith C et al. The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
10. Gladman DD, Urowitz MB, Goldsmith CH et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40:809-13.
11. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000; 43:1801-8.
12. Karp I, Abrahamowicz M, Fortin PR et al. Recent corticosteroid use and recent disease activity: Independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? Arthritis Rheum 2008;59:169-75.
13. Alarcon GS, Friedman AW, Straaton KV et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture. Lupus 1999;8:197-209.
14. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
15. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.
16. Reveille JD, Moulds JM, Ahn C et al. Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA Study Group. Lupus in minority populations, Nature versus Nurture. Arthritis Rheum 1998;41:1161-72.
17. U.S. Department of Commerce, Bureau of the Census. Current population reports, Series P-23, No. 28 and Series P-60, No. 68 and subsequent years. Washington, DC: Housing and Household Economic Statistics Division, 1995.
18. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
19. Gladman DD, Goldsmith CH, Urowitz MB et al. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation. J Rheumatol 1994;21:1468-71.
20. Aarden LA, De Groot ER, Feltkamp TE. Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann NY Acad Sci 1975;254:505-15.
21. Hamilton RG, Harley JB, Bias WB et al. Two Ro (SS-A) autoantibody responses in systemic lupus erythematosus. Correlation of HLA-DR/DQ specificities with quantitative expression of Ro (SS-A) autoantibody. Arthritis Rheum 1988;31: 496-505.
22. Harris EN. Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-phospholipid Antibody Study (KAPS) Group. Am J Clin Pathol 1990;94:476-84.
23. Triplett DA, Barna LK, Unger GA. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemost 1993;70:787-93.
24. Zonana-Nacach A, Camargo-Coronel A, Yanez P et al. Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: relationship with disease duration. Lupus 1998;7:119-23.
25. Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1955-9.
26. Koenig W, Sund M, Frohlich M et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-42.
27. Folsom AR, Aleksic N, Catellier D, Juneja HS, Wu KK. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J 2002;144:233-8.
28. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3.
29. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97:425-8.
30. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
31. Kao AH, Wasko MC, Krishnaswami S et al. C-reactive protein and coronary artery calcium in asymptomatic women with systemic lupus erythematosus or rheumatoid arthritis. Am J Cardiol 2008;102:755-60.
32. Bertoli AM, Vila LM, Reveill JD, Alarcon GS. Systemic lupus erythematosus in a multiethnic U.S. cohort (LUMINA): The value of high sensitivity C-reactive protein as a marker of disease activity and damage. J Rheumatol 2008;35:2355-8.
33. Lee SS, Singh S, Link K, Petri M. High-sensitivity c-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. Semin Arthritis Rheum 2008;38:54.
34. Danenberg HD, Szalai AJ, Swaminathan RV et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003;108:512-15.
35. Paul A, Ko KWS, Li L et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004;109:647-55.
36. Kiani AN, Mahoney JA, Petri M. Asymmetric dimethylarginine is a marker of poor prognosis and coronary calcium in systemic lupus erythematosus. J Rheumatol 2007;34:1502-5.
37. Baldassarre D, Porta B, Camera M et al. Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment. Nutr Metab Cardiovasc Dis. Advance Access published January 24, 2009, doi: 10.1016/j.numecd.2008.10.003.
38. Consuegra-Sanchez L, Fredericks S, Kaski JC. Pregnancy-associated plasma protein-A (PAPP-A) and cardiovascular risk. Atherosclerosis. 2009;203:346-52.
39. Rho YH, Chung CP, Oeser A et al. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J Rheumatol 2008;35:1789-94.
40. Ciferska H, Horak P, Hermanova Z et al. The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value. Clin Rheumatol 2007;26:723-8.
41. Andrade RM, Alarcon GS, Fernandez M, Apte M, Vila LM, Reveille JD. Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort. Arthritis Rheum 2007;56:622-30.
42. Garcia MA, Marcos JC, Marcos AI et al. Male systemic lupus erythematosus in a Latin-American inception cohort of 1214 patients. Lupus 2005;14:938-46.
43. Bertoli AM, Alarcon GS, Calvo-Alen J, Fernandez M, Vila LM, Reveille JD. Systemic lupus erythematosus in a multiethnic US cohort. XXXIII. Clinical [corrected] features, course, and outcome in patients with late-onset disease. Arthritis Rheum 2006;54:1580-7.
44. Asanuma Y, Oeser A, Shintani AK et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2407-15.
45. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis. Am J Med 1994;96:254-9.
46. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141:764-70.
47. Alarcon GS, McGwin G Jr, Bertoli AM et al. Effect of hydroxychloroquine in the survival of patients with systemic lupus erythematosus. Data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007;66:1168-72.
48. Tanay A, Leibovitz E, Frayman A, Zimlichman R, Shargorodsky M, Gavish D. Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment. Ann N Y Acad Sci 2007;1108:24-34.
49. Petri M. Hydroxychloroquine: Past, present, future. Lupus 1998;7:65-67.
50. Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994;20: 243-63.
51. Velagaleti RS, Vasan RS. Heart failure in the twenty-first century: Is it a coronary artery disease or hypertension problem? Cardiol Clin 2007;25:487-95.